XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of presentation (Tables)
3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Schedule Of Impact Of Restatement On Certain Line Items And Balance Sheet
The tables below present the impact of the revision on the line items within the Company’s consolidated financial statements for the relevant period:
 
     Three months ended  
     March 31, 2023  
     U.S $ in millions (except per share amounts)  
     (Unaudited)  
     As previously reported      Adjustment      As revised  
Other asset impairments, restructuring and other items
   $ 96        15        110  
Operating income (loss)
     2        (15      (13
Income (loss) before income taxes
     (258      (15      (272
Income taxes (benefit)
     (19    §        (19
Net income (loss)
     (238      (15      (253
Net income (loss) attributable to Teva
     (205      (15      (220
Earnings (loss) per share attributable to ordinary shareholders:         
Basic
   $ (0.18      (0.02      (0.20
Diluted
   $ (0.18      (0.02      (0.20
 
§
Represents an amount less than $0.5 million.